Tampa, FL—August 1st, 2013— AnazaoHealth Corporation announced today that it has signed a Patient Specific Brachytherapy Seed Loading Services Agreement with Accelyon Limited. Accelyon Limited is the recently launched UK-based company specialising in supplying brachytherapy seeds, loaded seed assemblies and associated accessories and equipment to hospitals and clinics worldwide. Under the agreement, AnazaoHealth will load patient specific prescriptions of brachytherapy seeds into needles, cartridges and stranded assemblies for Accelyon to distribute to public and private hospitals in the European Union, Australia and New Zealand.
“AnazaoHealth’s brachytherapy seed assemblies have a long-established high quality reputation in the European and Australasia brachytherapy marketplaces,” said Saheed Rashid, Managing Director of Accelyon. “We are committed to delivering the highest standards of quality and reliability to our customers whose clearly stated preference is for Accelyon to supply AnazaoHealth seed presentations. Having previously announced our brachytherapy seed supply agreement with Theragenics, today’s announcement completes Accelyon’s product offerings and positions our company perfectly for meeting the needs of our hospital customers in all of our target markets.”
“Whilst Accelyon is a new entrant into the brachytherapy marketplace, the company has a highly experienced team who know the market extremely well,” said Chris A Arnette, President and Chief Operating Officer of AnazaoHealth Corporation. “We are confident that Accelyon can quickly build a strong business in Europe and Australasia and we are delighted to have been selected to provide their loading services requirements. AnazaoHealth believes there is an opportunity for brachytherapy to strengthen its position against competing early stage treatments and we look forward to working with Accelyon to pursue this attractive opportunity.”
Prostate cancer is the second most common form of cancer and the sixth leading cause of cancer deaths in men worldwide. Brachytherapy is a proven treatment with over 20 years’ history and an increasing base of clinical evidence to support both its effectiveness as an early stage therapy and its favourable side effect profile compared with other prostate cancer treatments1,2,3.
Since 1997, AnazaoHealth Corporation has created innovative patient specific preparations serving the nuclear medicine, pain management and custom pharmacy markets, as well as providing drugs used in clinical trials. We are headquartered in Tampa, FL with an additional facility in Las Vegas, NV.
AnazaoHealth is a pharmacy that specializes in compounding sterile preparations and is fully licensed to provide nuclear, radioactive materials and DEA controlled substances in all 50 states. AnazaoHealth is both 797 and PCAB accredited.
The word Anazao (phonetically pronounced an-ah-zah’-o) in Greek means “to come alive again” or “to recover life”. At AnazaoHealth we are dedicated to create and provide the most powerful innovations in healing for our patients.
About Accelyon Limited
Committed to the future of Brachytherapy
For more information contact:
Saheed Rashid (Managing Director – Accelyon Limited)
1. Accelyon Limited is a UK company with head office at Capital Point, 33 Bath Road, Slough SL1 3UF and Registered Office at 64 New Cavendish Street, London W1G 8TB; Company Registration 08252168.
2. The world market for prostate cancer treatment is growing driven by increasing patient awareness, improving imaging technologies and readily available screening. A recent paper published in the European Journal of Urology on international variation in prostate cancer incidence and mortality rates (March 2012) estimated 899,000 new cases and 258,000 prostate cancer deaths in 2008. It further predicted 1.7 million new cases and 499,000 deaths by 20304 representing a doubling of the patient population worldwide.
1. Grimm P et al. BJU International 2012; 109, supplement 1: 22-29
2. Malcolm JB et al. Journal of Urology 2010; 183: 1822-29
3. Chen RC et al. J Clin Oncol 2009; 27: 3916-22
4. EAU International Variation in Prostate Cancer Incidence and Mortality Rates